Detalhe da pesquisa
1.
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.
Immunol Rev
; 318(1): 157-166, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37470280
2.
Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series.
Oncologist
; 28(9): e839-e842, 2023 09 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37338166
3.
Public Health Risks, Dermatological Manifestations, and Environmental Justice Associated With Vinyl Chloride Exposure: Narrative Review.
JMIR Dermatol
; 6: e48998, 2023 Sep 07.
Artigo
Inglês
| MEDLINE | ID: mdl-37676716
4.
Corticosteroids and Cancer Immunotherapy.
Clin Cancer Res
; 29(14): 2580-2587, 2023 07 14.
Artigo
Inglês
| MEDLINE | ID: mdl-36648402
5.
On the cusp: Considering the impact of artificial intelligence language models in healthcare.
Med
; 4(3): 139-140, 2023 03 10.
Artigo
Inglês
| MEDLINE | ID: mdl-36905924
6.
Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
JAMA Netw Open
; 6(8): e2327145, 2023 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-37535354
7.
Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.
Eur J Cancer
; 194: 113354, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37827067
8.
Accuracy and Reliability of Chatbot Responses to Physician Questions.
JAMA Netw Open
; 6(10): e2336483, 2023 10 02.
Artigo
Inglês
| MEDLINE | ID: mdl-37782499
9.
Cost assessment in melanoma clinical trials: A cross-sectional study.
JAAD Int
; 12: 139-141, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37409320
10.
Delayed and persistent multisystem toxicities of adjuvant anti-PD-1 therapy for stage III melanoma.
Eur J Cancer
; 192: 113255, 2023 10.
Artigo
Inglês
| MEDLINE | ID: mdl-37595488